Seaport Therapeutics, INC

Seaport Therapeutics announced its second quarter 2026 financial results, detailing progress in its clinical trials for major depressive disorder and generalized anxiety disorder, alongside a robust cash position post-IPO.

Seaport Therapeutics, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing increased R&D expenses and substantial operating losses, while noting sufficient cash runway into 2029.

Seaport Therapeutics Director Robert J. Hombach acquired 13,000 shares of common stock in a transaction on June 22, 2026.

Daphne Zohar has disclosed a beneficial ownership of 9.1% in Seaport Therapeutics, Inc., holding over 5.2 million shares.